A Phase 3 interventional study of AA4500 and Placebo in Peyronie's Disease, sponsored by Endo Pharmaceuticals. Completed at 34 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.
Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing Microbial Collagenase in Penile Induration — none open to participants now, 3 under way, none of them phase 3. Microbial Collagenase · Penile Induration.
Among the 13 studies testing Microbial Collagenase in Penile Induration, this one has the largest enrollment, is one of 3 that started in 2010, is one of 4 in phase 3, and was the 2nd registered.
48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.
Browse Penile Induration studies →None of the 13 studies testing Microbial Collagenase in Penile Induration is open now. The open studies under Penile Induration, anywhere →
Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 8 Penile Induration studies recruiting now, 5 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2010.
This study's enrollment of 418 is above the median of 40 across 40 interventional studies indexed under Penile Induration.
Median enrollment 40 across the 13 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 6 most frequent:
This study is registered under Endo Pharmaceuticals, one of the names counted as Keenova Therapeutics plc. Under that name alone:
Endo Pharmaceuticals is the lead sponsor of 99 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Keenova Therapeutics plc has 9 studies filed under Penile Induration — fewer than ten, so there is no comparison to draw.
2 of the studies testing Microbial Collagenase in Penile Induration that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT04786106Charitable Union for the Research and Education of Peyronie's DiseaseInvestigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's | 2027-02-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing Microbial Collagenase in Penile Induration, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle.
Before dosing, subjects will be stratified by degree of penile curvature deformity (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo.
In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15 degrees after the first, second, or third cycle of injections or if further treatment is not clinically indicated, subsequent treatment cycles will not be administered.
Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Has any of the following conditions:
Has, at any time, received AA4500 for the treatment of Peyronie's disease
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
collagenase clostridium histolyticum
Biological: AA4500
placebo
Biological: Placebo
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Also known as: XIAFLEX
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Percentage Change From Baseline in Penile Curvature
A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.
Time frame: Baseline and Week 52
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)
Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.
Time frame: Baseline and Week 52
A Responder Analysis Based on Subject Overall Global Assessment of Peyronie's Disease
A responder was defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question.
Time frame: Week 52
Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms
Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.
Time frame: Baseline and Week 52
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)
Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.
Time frame: Baseline and Week 52
Change From Baseline in Penile Plaque Consistency
Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline score in penile plaque consistency is indicated by a negative number.
Time frame: Baseline and Week 52
Change From Baseline in Penile Length
A negative value represents a reduction in measurement from baseline.
Time frame: Baseline and Week 52
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4
Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.
Time frame: Baseline and Week 52
Composite Responder Based on Change in Curvature Deformity and Change in Peyronie's Disease Bother Score
A responder was defined as a subject who satisfied the following 2 criteria at that visit: a) percent reduction from baseline in curvature deformity was ≥20% and b) reduction from baseline in PDQ Peyronie's disease bother score was ≥1, or had a change from reporting no sexual activity at screening to reporting sexual activity.
Time frame: Week 52
| Milestone | AA4500 | Placebo |
|---|---|---|
| Started | 277 | 140 |
| Completed | 241 | 124 |
| Not completed | 36 | 16 |
| Withdrew: Adverse event | 4 | 1 |
| Withdrew: Withdrawal by subject | 20 | 6 |
| Withdrew: Lost to follow-up | 6 | 5 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Other | 3 | 4 |
| Withdrew: Death | 2 | 0 |
A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.
| percentage of curvature change | AA4500 | Placebo |
|---|---|---|
| Percentage Change From Baseline in Penile Curvature | -37.6 ± 30.29 | -21.3 ± 29.89 |
Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ) | -3.3 ± 3.83 | -2.0 ± 3.53 |
A responder was defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question.
| Number of particpants | AA4500 | Placebo |
|---|---|---|
| Responder Status-No | 67 | 73 |
| Responder Status-Yes | 131 | 30 |
| Responder Status-Missing | 1 | 1 |
Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms | -3.2 ± 5.23 | -1.6 ± 4.50 |
Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF) | 1.0 ± 2.55 | 0.5 ± 2.42 |
Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline score in penile plaque consistency is indicated by a negative number.
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in Penile Plaque Consistency | -0.7 ± 0.97 | -0.6 ± 0.84 |
A negative value represents a reduction in measurement from baseline.
| centimeters | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in Penile Length | 0.4 ± 1.29 | 0.1 ± 1.11 |
Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.
| units on a scale | AA4500 | Placebo |
|---|---|---|
| Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4 | -5.1 ± 5.16 | -4.0 ± 4.09 |
A responder was defined as a subject who satisfied the following 2 criteria at that visit: a) percent reduction from baseline in curvature deformity was ≥20% and b) reduction from baseline in PDQ Peyronie's disease bother score was ≥1, or had a change from reporting no sexual activity at screening to reporting sexual activity.
| Number of participants | AA4500 | Placebo |
|---|---|---|
| Responder Status No | 129 | 97 |
| Responder Status yes | 132 | 33 |
| Responder- Missing | 16 | 10 |
Collected over Throughout the study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AA4500 | — | 27/277 (9.7%) | 248/277 (89.5%) |
| Placebo | — | 7/140 (5%) | 55/140 (39.3%) |
| Event | AA4500 | Placebo |
|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/277 | 0/140 |
| Road traffic accidentInjury, poisoning and procedural complications | 2/277 | 0/140 |
| Penile hematomaReproductive system and breast disorders | 2/277 | 0/140 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/277 | 1/140 |
| SciaticaNervous system disorders | 1/277 | 1/140 |
| AppendicitisInfections and infestations | 0/277 | 1/140 |
| Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/277 | 1/140 |
| Carcinoma in situ penisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/277 | 1/140 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/277 | 1/140 |
| DiverticulumGastrointestinal disorders | 0/277 | 1/140 |
| Event | AA4500 | Placebo |
|---|---|---|
| Penile haematomaReproductive system and breast disorders | 171/277 | 19/140 |
| Penile painReproductive system and breast disorders | 119/277 | 11/140 |
| Penile swellingReproductive system and breast disorders | 114/277 | 1/140 |
| Injection site painGeneral disorders | 70/277 | 5/140 |
| Penile haemorrhageReproductive system and breast disorders | 60/277 | 14/140 |
| injection site haematomaGeneral disorders | 45/277 | 14/140 |
| Penile oedemaReproductive system and breast disorders | 45/277 | 1/140 |
| Injection site swellingGeneral disorders | 30/277 | 0/140 |
| ContusionInjury, poisoning and procedural complications | 28/277 | 0/140 |
| EcchymosisSkin and subcutaneous tissue disorders | 26/277 | 0/140 |
| Age, Categorical(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 226 | 108 | 334 |
| >=65 years | 51 | 32 | 83 |
| Age, Continuous(years) | AA4500 | Placebo | Total |
|---|---|---|---|
| Mean | 57.9 ± 8.22 | 58.2 ± 8.94 | 58.0 ± 8.46 |
| Sex: Female, Male(Participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 277 | 140 | 417 |
| Region of Enrollment(participants) | AA4500 | Placebo | Total |
|---|---|---|---|
| United States | 223 | 113 | 336 |
| Australia | 54 | 27 | 81 |
The record gives a start of Sep 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Microbial Collagenase